Compare FLXS & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLXS | TLSI |
|---|---|---|
| Founded | 2001 | 2010 |
| Country | United States | United States |
| Employees | N/A | 102 |
| Industry | Home Furnishings | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 290.6M | 270.2M |
| IPO Year | 1995 | N/A |
| Metric | FLXS | TLSI |
|---|---|---|
| Price | $76.89 | $4.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $54.00 | $7.00 |
| AVG Volume (30 Days) | 37.0K | ★ 208.5K |
| Earning Date | 04-20-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.41% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 3.63 | N/A |
| Revenue | ★ $441,073,000.00 | N/A |
| Revenue This Year | $4.51 | $35.45 |
| Revenue Next Year | $4.89 | $37.58 |
| P/E Ratio | $21.31 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $32.65 | $2.20 |
| 52 Week High | $79.70 | $7.95 |
| Indicator | FLXS | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Flexsteel Industries Inc is a United States-based company that manufactures, imports, and markets residential upholstered wooden furniture products. Its product offerings include sofas, loveseats, chairs, rockers, desks, tables, convertible bedding units, and bedroom furniture. The company's products are intended for use in home, office, hotel, healthcare, and other contract applications. A featured component in the company's upholstered furniture is the durable Blue Steel Spring. It operates in the business segment of Furniture products. The company's furniture products business involves the distribution of manufactured and imported products for residential markets.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.